Cited by 40Treatment of Major DepressionNerve injury and regenerationNeurotransmitter Receptor Influence on Behavior

Targeting TrkB neurotrophin receptor to treat depression

Rantamäki, Tomi, Castrén, Eero·2008·Expert Opinion on Therapeutic Targets

Abstract

Background An increasing number of findings point out the key role of the BDNF (brain-derived neurotrophic factor) receptor, tyrosine kinase receptor B (TrkB), in the regulation of antidepressant drug actions. Therefore, targeting TrkB receptors might be a rational strategy to develop novel antidepressant drugs. Objective/methods In this review we will discuss several approaches to targeting the TrkB receptor using existing or novel drugs. We will mainly concentrate on the following issues: i) synthesis, release and cleavage of neurotrophins; ii) augmentation of the actions of neurotrophins; iii) synthesis of TrkB; iv) developing agonists for TrkB; and v) TrkB transactivation. Conclusions Different molecular approaches can be used to screen antidepressant drugs acting through TrkB receptors but it remains to be seen whether they demonstrate therapeutic antidepressant effects.

Integrity signals

Registry

Crossref · 10.1517/14728222.12.6.705

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Close molecular connections between serotonergic receptors and neurotrophic proteins such as BDNF and intracellular signaling cascades are responsible for cytoskeletal rearrangement.

    “Close molecular connections between serotonergic receptors and neurotrophic proteins as brain-derived neurotrophic factor (BDNF) and intracellular signaling cascades are responsible for cytoskeletal rearrangement (Mattson et al., 2004;Rantamaki and Castren, 2008); see Table 1).”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Rantamäki, T., & Castrén, E.
Affiliations
University of Helsinki (FI)
Venue
Expert Opinion on Therapeutic Targets
Published
2008-05-15
Volume
12
Issue
6
Pages
705-715
ISSN
  • 1472-8222 (ISSN-L)
  • 1744-7631
OpenAlex
W2051770438
Cited by
40
References
18
Citations by year
2025: 4 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 3 · 2020: 1 · 2019: 3 · 2017: 2 · 2016: 2 · 2015: 3 · 2014: 1 · 2013: 2 · 2012: 2
FWCI
0.40
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Therapeutic Targets (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
TrkB receptor, brain-derived neurotrophic factor, depression, antidepressant drug development, TrkB agonist
MeSH terms
Animals, Antidepressive Agents, Depression, Humans, Brain-Derived Neurotrophic Factor, Receptor, trkB

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review